001     289486
005     20240508085855.0
024 7 _ |a 10.1021/acsnano.3c08335
|2 doi
024 7 _ |a pmid:38626916
|2 pmid
024 7 _ |a 1936-0851
|2 ISSN
024 7 _ |a 1936-086X
|2 ISSN
024 7 _ |a altmetric:162570334
|2 altmetric
037 _ _ |a DKFZ-2024-00808
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Horvat, Natalie K
|b 0
245 _ _ |a Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment.
260 _ _ |a Washington, DC
|c 2024
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1715151447_22381
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:B220# / 2024 Apr 30;18(17):11025-11041
520 _ _ |a ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor (TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor survival rates. Growing evidence suggests that the combination of drug and immune therapies greatly improves patient survival; however, due to the low immunogenicity of the tumors, ALK-positive patients do not respond to currently available immunotherapies. Tumor-associated macrophages (TAMs) play a crucial role in facilitating lung cancer growth by suppressing tumoricidal immune activation and absorbing chemotherapeutics. However, they can also be programmed toward a pro-inflammatory tumor suppressive phenotype, which represents a highly active area of therapy development. Iron loading of TAMs can achieve such reprogramming correlating with an improved prognosis in lung cancer patients. We previously showed that superparamagnetic iron oxide nanoparticles containing core-cross-linked polymer micelles (SPION-CCPMs) target macrophages and stimulate pro-inflammatory activation. Here, we show that SPION-CCPMs stimulate TAMs to secrete reactive nitrogen species and cytokines that exert tumoricidal activity. We further show that SPION-CCPMs reshape the immunosuppressive Eml4-Alk lung tumor microenvironment (TME) toward a cytotoxic profile hallmarked by the recruitment of CD8+ T cells, suggesting a multifactorial benefit of SPION-CCPM application. When intratracheally instilled into lung cancer-bearing mice, SPION-CCPMs delay tumor growth and, after first line therapy with a TKI, halt the regrowth of relapsing tumors. These findings identify SPIONs-CCPMs as an adjuvant therapy, which remodels the TME, resulting in a delay in the appearance of resistant tumors.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a adjuvant therapy
|2 Other
650 _ 7 |a iron homeostasis
|2 Other
650 _ 7 |a lung cancer
|2 Other
650 _ 7 |a nanoparticle
|2 Other
650 _ 7 |a polymeric micelle
|2 Other
700 1 _ |a Chocarro, Sara
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Marques, Oriana
|b 2
700 1 _ |a Bauer, Tobias A
|b 3
700 1 _ |a Qiu, Ruiyue
|b 4
700 1 _ |a Diaz-Jimenez, Alberto
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Helm, Barbara
|0 P:(DE-He78)1c49e2bc4134e93b5dc7d9845e30c039
|b 6
|u dkfz
700 1 _ |a Chen, Yuanyuan
|0 P:(DE-He78)cb1c1075d6ce2a1d20a7c74232e56c18
|b 7
700 1 _ |a Sawall, Stefan
|0 P:(DE-He78)14909c75431f33f953a7ab4ad3bd7d51
|b 8
|u dkfz
700 1 _ |a Sparla, Richard
|b 9
700 1 _ |a Su, Lu
|0 0000-0001-8207-756X
|b 10
700 1 _ |a Klingmüller, Ursula
|0 P:(DE-He78)860df4ab16c373fb28a815dcd81107a6
|b 11
|u dkfz
700 1 _ |a Barz, Matthias
|0 0000-0002-1749-9034
|b 12
700 1 _ |a Hentze, Matthias W
|b 13
700 1 _ |a Sotillo, Rocío
|0 P:(DE-HGF)0
|b 14
|e Last author
700 1 _ |a Muckenthaler, Martina U
|b 15
773 _ _ |a 10.1021/acsnano.3c08335
|g p. acsnano.3c08335
|0 PERI:(DE-600)2383064-5
|n 17
|p 11025-11041
|t ACS nano
|v 18
|y 2024
|x 1936-0851
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289486
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)1c49e2bc4134e93b5dc7d9845e30c039
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)cb1c1075d6ce2a1d20a7c74232e56c18
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)14909c75431f33f953a7ab4ad3bd7d51
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)860df4ab16c373fb28a815dcd81107a6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-10-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACS NANO : 2022
|d 2023-10-25
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b ACS NANO : 2022
|d 2023-10-25
920 2 _ |0 I:(DE-He78)B220-20160331
|k B220
|l B220 Molekulare Grundlagen thorakaler Tumoren
|x 0
920 1 _ |0 I:(DE-He78)B220-20160331
|k B220
|l B220 Molekulare Grundlagen thorakaler Tumoren
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B200-20160331
|k B200
|l B200 Systembiologie der Signaltransduktion
|x 2
920 1 _ |0 I:(DE-He78)E025-20160331
|k E025
|l E025 Röntgenbildgebung und Computertomographie
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B220-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B200-20160331
980 _ _ |a I:(DE-He78)E025-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21